Fact Source: Financial Supervisory Service DART / 2025-10-23
Disclosure Type: Suspension and Resumption of Trading
💡 3-Second Summary
Due to administrative procedures involving the alteration and cancellation of electronic stock registrations for a corporate split, trading for Samsung Biologics stock will be suspended starting October 30, 2025, and will officially resume on the upcoming relisting date.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Target Security: Samsung Biologics Co., Ltd. Share certificates
- Trading Suspension Date: From October 30, 2025
- Trading Resumption Date: The altered listing date (Relisting date)
- Reason for Trading Suspension (Lifting): Modification and cancellation of electronic registration due to corporate split
- Governing Regulation: Article 153 of the KOSPI Market Listing Regulation
- Note: The explicit calendar date for the relisting and trading resumption is not specified in the original text.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing indicates a temporary halt in the trading of Samsung Biologics shares starting from a specific date. Rather than representing a negative shift in the company’s underlying operating performance or financial fundamental health, this action serves as a mandatory administrative procedure required to facilitate the corporate split.
The primary points for market participants to register are that stock trading will be unavailable starting October 30, 2025, and the resumption timeline is tied to the altered listing date rather than a fixed calendar day. Governed by KOSPI market listing rules, this corporate action means that investor liquidity will be temporarily restricted during the suspension window. This specific text does not detail the underlying method of the corporate split or outline the precise corporate schedule for the upcoming relisting.
In conclusion, the schedule for the trading suspension linked to the corporate split is verified through this filing. Because the exact date for trading resumption remains bound to the future relisting timeline, market participants should follow subsequent disclosures regarding the finalized relisting date and monitored split progression.
📝 Editor’s Comment (by K-STOCK Editor)
Shareholders holding exposure in Samsung Biologics must register the fact that stock trading will be completely halted starting October 30, 2025. This suspension is a structural requirement designed to accommodate necessary registration modifications and cancellations for the corporate split. Currently, the exact calendar date for the relisting and subsequent trading resumption is not detailed within this text, making it difficult to project the precise duration of the suspension from this filing alone. Market participants should avoid speculative trading assumptions during this window and instead prioritize following subsequent updates regarding the official relisting schedule to manage portfolio risk appropriately.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
